Brokerages Set NewAmsterdam Pharma (NASDAQ:NAMS) Target Price at $43.33

Shares of NewAmsterdam Pharma (NASDAQ:NAMSGet Free Report) have been assigned a consensus rating of “Buy” from the six ratings firms that are presently covering the firm, MarketBeat Ratings reports. Six analysts have rated the stock with a buy rating. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $43.33.

Several analysts recently commented on the stock. Royal Bank of Canada reissued an “outperform” rating and set a $40.00 target price on shares of NewAmsterdam Pharma in a research note on Friday, January 24th. Needham & Company LLC cut their target price on shares of NewAmsterdam Pharma from $46.00 to $42.00 and set a “buy” rating for the company in a research note on Thursday, February 27th. HC Wainwright reissued a “buy” rating and set a $48.00 target price on shares of NewAmsterdam Pharma in a research note on Tuesday, January 14th. Scotiabank increased their target price on shares of NewAmsterdam Pharma from $47.00 to $52.00 and gave the company a “sector outperform” rating in a research note on Thursday, February 27th. Finally, UBS Group set a $41.00 price target on shares of NewAmsterdam Pharma in a report on Monday, March 3rd.

Get Our Latest Analysis on NewAmsterdam Pharma

NewAmsterdam Pharma Stock Performance

NAMS opened at $23.37 on Tuesday. The company has a 50-day moving average of $21.95 and a 200-day moving average of $20.75. The company has a market capitalization of $2.57 billion, a P/E ratio of -8.99 and a beta of -0.04. NewAmsterdam Pharma has a 1-year low of $15.19 and a 1-year high of $27.29.

NewAmsterdam Pharma (NASDAQ:NAMSGet Free Report) last announced its quarterly earnings data on Wednesday, February 26th. The company reported ($0.95) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.47). The company had revenue of $12.77 million for the quarter, compared to analyst estimates of $3.30 million. As a group, sell-side analysts expect that NewAmsterdam Pharma will post -1.75 earnings per share for the current fiscal year.

Insider Buying and Selling at NewAmsterdam Pharma

In other NewAmsterdam Pharma news, major shareholder Nap B.V. Forgrowth sold 49,772 shares of the business’s stock in a transaction that occurred on Friday, December 20th. The shares were sold at an average price of $25.60, for a total value of $1,274,163.20. Following the completion of the sale, the insider now directly owns 10,802,224 shares of the company’s stock, valued at $276,536,934.40. The trade was a 0.46 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CAO Louise Frederika Kooij sold 150,000 shares of the business’s stock in a transaction that occurred on Tuesday, March 4th. The stock was sold at an average price of $20.37, for a total transaction of $3,055,500.00. Following the completion of the sale, the chief accounting officer now directly owns 15,000 shares of the company’s stock, valued at $305,550. This represents a 90.91 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 388,916 shares of company stock worth $9,231,268. 19.50% of the stock is currently owned by company insiders.

Institutional Trading of NewAmsterdam Pharma

Several large investors have recently added to or reduced their stakes in NAMS. TimesSquare Capital Management LLC grew its position in NewAmsterdam Pharma by 3.7% in the third quarter. TimesSquare Capital Management LLC now owns 255,245 shares of the company’s stock worth $4,237,000 after acquiring an additional 9,160 shares in the last quarter. Lisanti Capital Growth LLC bought a new stake in shares of NewAmsterdam Pharma during the 3rd quarter worth $700,000. GSA Capital Partners LLP boosted its holdings in shares of NewAmsterdam Pharma by 79.9% during the 3rd quarter. GSA Capital Partners LLP now owns 66,402 shares of the company’s stock worth $1,102,000 after buying an additional 29,496 shares during the period. Jennison Associates LLC boosted its holdings in shares of NewAmsterdam Pharma by 8.9% during the 3rd quarter. Jennison Associates LLC now owns 1,020,278 shares of the company’s stock worth $16,937,000 after buying an additional 83,115 shares during the period. Finally, HealthInvest Partners AB boosted its holdings in shares of NewAmsterdam Pharma by 83.4% during the 3rd quarter. HealthInvest Partners AB now owns 138,983 shares of the company’s stock worth $2,307,000 after buying an additional 63,189 shares during the period. 89.89% of the stock is owned by institutional investors.

NewAmsterdam Pharma Company Profile

(Get Free Report

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.

Recommended Stories

Analyst Recommendations for NewAmsterdam Pharma (NASDAQ:NAMS)

Receive News & Ratings for NewAmsterdam Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewAmsterdam Pharma and related companies with MarketBeat.com's FREE daily email newsletter.